Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart + Anlotinib vs Sunitinib in Advanced Renal Cancer
NCT04523272Phase 3Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2020
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart in clear cell renal cell carcinoma (ccRCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2020; status: active, not recruiting.
02
Drugs
benmelstobart
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04523272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523272.